Research graph
References from The AURKA–PTTG1 signaling axis induces enzalutamide resistance in prostate cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Prostate cancer
10.1016/s0140-6736(21)00950-8 · 2021 · External reference
Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management
10.1097/mou.0000000000000984 · 2022 · External reference
Resistance to antiandrogens in prostate cancer: is it inevitable, intrinsic or induced?
10.3390/cancers13020327 · 2021 · External reference
The neglected liaison: targeting cancer cell metabolic reprogramming modifies the composition of non-malignant populations of the tumor microenvironment
10.3390/cancers13215447 · 2021 · External reference
Modulating glycolysis to improve cancer therapy
10.3390/ijms24032606 · 2023 · External reference
Glycolysis-induced drug resistance in tumors-A response to danger signals?
10.1016/j.neo.2020.12.009 · 2021 · External reference
PD44-12 enzalutamide enhances glycolysis in castration-resistant prostate cancer
10.1097/ju.0000000000002058.12 · 2021 · External reference
Basic mechanism of eukaryotic chromosome segregation
10.1098/rstb.2004.1615 · 2005 · External reference
Separase: a universal trigger for sister chromatid disjunction but not chromosome cycle progression
10.1083/jcb.200506119 · 2006 · External reference
Multi-omics analysis identifies PTTG1 as a prognostic biomarker associated with immunotherapy and chemotherapy resistance
10.1186/s12885-024-13060-5 · 2024 · External reference
Elevated PTTG1 predicts poor prognosis in kidney renal clear cell carcinoma and correlates with immunity
10.1016/j.heliyon.2023.e13201 · 2023 · External reference
A comprehensive pan-cancer analysis for pituitary tumor-transforming gene 1
10.3389/fgene.2022.843579 · 2022 · External reference
CDC20 and PTTG1 are important biomarkers and potential therapeutic targets for metastatic prostate cancer
10.1007/s12325-021-01729-3 · 2021 · External reference
Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression
10.1111/cas.13493 · 2018 · External reference
Aurora kinases, emerging critical targets for cancer treatment and related new therapeutic strategies
10.1016/j.bioorg.2025.108633 · 2025 · External reference
Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features
10.1186/s13058-024-01882-x · 2024 · External reference
FBXO44 Regulates FOXP1 degradation through AURKA-dependent phosphorylation to promote colorectal cancer progression
2025 · External reference
The oncogenic role of AURKA in gastric cancer: mechanisms, pathways, and clinical relevance
10.1093/carcin/bgaf054 · 2025 · External reference
HMMR promotes prostate cancer proliferation and metastasis via AURKA/mTORC2/E2F1 positive feedback loop
10.1038/s41420-023-01341-0 · 2023 · External reference
Neurokinin-1 receptor drives PKCa-AURKA/N-myc signaling to facilitate the neuroendocrine progression of prostate cancer
10.1038/s41419-023-05894-x · 2023 · External reference
Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA
10.1080/07853890.2023.2282184 · 2024 · External reference
ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer
2025 · External reference
Integrating quantitative proteomics with accurate genome profiling of transcription factors by greenCUT&RUN
10.1093/nar/gkab038 · 2021 · External reference
Identification of protein subcellular localization with network and functional embeddings
2020 · External reference
Phosphorylated PTTG1 switches its subcellular distribution and promotes beta-catenin stabilization and subsequent transcription activity
10.1038/s41388-023-02767-7 · 2023 · External reference
Inhibition of PTTG1 suppresses proliferation and promotes differentiation of neuroblastoma cells by inducing autophagy
10.1007/s00383-025-06246-w · 2025 · External reference
The PTTG1/VASP axis promotes oral squamous cell carcinoma metastasis by modulating focal adhesion and actin filaments
10.1002/1878-0261.13779 · 2025 · External reference
PTTG1-mediated reprogramming of asparagine metabolism enhances DNA damage repair and leads to compromised antitumor immunity in prostate cancer
10.1016/j.urolonc.2025.09.005 · 2026 · External reference
EIF4A3-Induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2/c-Myc/LDHA signaling
10.1158/0008-5472.can-21-2988 · 2022 · External reference
Glycolysis related lncRNA SNHG3 /miR-139-5p / PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance
2024 · External reference
The cellular geography of aurora kinases
10.1038/nrm1245 · 2003 · External reference
Meningioma achieves malignancy and erastin-induced ferroptosis resistance through FOXM1-AURKA-NRF2 axis
10.1016/j.redox.2024.103137 · 2024 · External reference
CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine
10.3389/fendo.2022.1106175 · 2022 · External reference
Evaluation of Alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial
10.1001/jamaoncol.2022.7949 · 2023 · External reference
Evaluation of Alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial
10.1001/jamaoncol.2022.7949 · ExternalCitation · doi-reference
The PTTG1/VASP axis promotes oral squamous cell carcinoma metastasis by modulating focal adhesion and actin filaments
10.1002/1878-0261.13779 · ExternalCitation · doi-reference
Inhibition of PTTG1 suppresses proliferation and promotes differentiation of neuroblastoma cells by inducing autophagy
10.1007/s00383-025-06246-w · ExternalCitation · doi-reference
CDC20 and PTTG1 are important biomarkers and potential therapeutic targets for metastatic prostate cancer
10.1007/s12325-021-01729-3 · ExternalCitation · doi-reference
Aurora kinases, emerging critical targets for cancer treatment and related new therapeutic strategies
10.1016/j.bioorg.2025.108633 · ExternalCitation · doi-reference
Elevated PTTG1 predicts poor prognosis in kidney renal clear cell carcinoma and correlates with immunity
10.1016/j.heliyon.2023.e13201 · ExternalCitation · doi-reference
Glycolysis-induced drug resistance in tumors-A response to danger signals?
10.1016/j.neo.2020.12.009 · ExternalCitation · doi-reference
Meningioma achieves malignancy and erastin-induced ferroptosis resistance through FOXM1-AURKA-NRF2 axis
10.1016/j.redox.2024.103137 · ExternalCitation · doi-reference
PTTG1-mediated reprogramming of asparagine metabolism enhances DNA damage repair and leads to compromised antitumor immunity in prostate cancer
10.1016/j.urolonc.2025.09.005 · ExternalCitation · doi-reference
Prostate cancer
10.1016/s0140-6736(21)00950-8 · ExternalCitation · doi-reference
The cellular geography of aurora kinases
10.1038/nrm1245 · ExternalCitation · doi-reference
Phosphorylated PTTG1 switches its subcellular distribution and promotes beta-catenin stabilization and subsequent transcription activity
10.1038/s41388-023-02767-7 · ExternalCitation · doi-reference
Neurokinin-1 receptor drives PKCa-AURKA/N-myc signaling to facilitate the neuroendocrine progression of prostate cancer
10.1038/s41419-023-05894-x · ExternalCitation · doi-reference
HMMR promotes prostate cancer proliferation and metastasis via AURKA/mTORC2/E2F1 positive feedback loop
10.1038/s41420-023-01341-0 · ExternalCitation · doi-reference
Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA
10.1080/07853890.2023.2282184 · ExternalCitation · doi-reference
Separase: a universal trigger for sister chromatid disjunction but not chromosome cycle progression
10.1083/jcb.200506119 · ExternalCitation · doi-reference
The oncogenic role of AURKA in gastric cancer: mechanisms, pathways, and clinical relevance
10.1093/carcin/bgaf054 · ExternalCitation · doi-reference
Integrating quantitative proteomics with accurate genome profiling of transcription factors by greenCUT&RUN
10.1093/nar/gkab038 · ExternalCitation · doi-reference
PD44-12 enzalutamide enhances glycolysis in castration-resistant prostate cancer
10.1097/ju.0000000000002058.12 · ExternalCitation · doi-reference
Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management
10.1097/mou.0000000000000984 · ExternalCitation · doi-reference
Basic mechanism of eukaryotic chromosome segregation
10.1098/rstb.2004.1615 · ExternalCitation · doi-reference
Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression
10.1111/cas.13493 · ExternalCitation · doi-reference
EIF4A3-Induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2/c-Myc/LDHA signaling
10.1158/0008-5472.can-21-2988 · ExternalCitation · doi-reference
Multi-omics analysis identifies PTTG1 as a prognostic biomarker associated with immunotherapy and chemotherapy resistance
10.1186/s12885-024-13060-5 · ExternalCitation · doi-reference
Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features
10.1186/s13058-024-01882-x · ExternalCitation · doi-reference
CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine
10.3389/fendo.2022.1106175 · ExternalCitation · doi-reference
A comprehensive pan-cancer analysis for pituitary tumor-transforming gene 1
10.3389/fgene.2022.843579 · ExternalCitation · doi-reference
Resistance to antiandrogens in prostate cancer: is it inevitable, intrinsic or induced?
10.3390/cancers13020327 · ExternalCitation · doi-reference
The neglected liaison: targeting cancer cell metabolic reprogramming modifies the composition of non-malignant populations of the tumor microenvironment
10.3390/cancers13215447 · ExternalCitation · doi-reference
Modulating glycolysis to improve cancer therapy
10.3390/ijms24032606 · ExternalCitation · doi-reference
